SCHEMBL1129496

SCHEMBL1129496

O=CNC(c1ccc(Oc2ccccc2)cc1)c1nccnc1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.34
LMNA P02545 3/20 0.33
KDM4E B2RXH2 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KMT2A Q03164 2/20 0.33
KCNQ3 O43525 1/20 0.33
KCNQ2 O43526 1/20 0.33
KCNE1 P15382 1/20 0.33
KCNQ1 P51787 1/20 0.33
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KAT2B Q92831 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL1129203 0.96 SRD5A2 (0.32) SRD5A2LMNAKDM4ERAB9ASMN1; SMN2
SCHEMBL2463376 0.78 MAOA (0.47) LMNASMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL19729793 0.77 ACACB (0.43) KDM4ERAB9ASMN1; SMN2KMT2AACACB
SCHEMBL17902729 0.77 PDE4A (0.36) LMNAKDM4ESMN1; SMN2ACACBACACA
SCHEMBL410225 0.75 SRD5A2 (0.39) SRD5A2TSHR
SCHEMBL410107 0.75 SRD5A2 (0.49) SRD5A2LMNAKMT2AMEN1IGFBP3
SCHEMBL17895943 0.75 PDE4A (0.32) LMNAKDM4ESMN1; SMN2ACACBACACA
SCHEMBL1129314 0.75 LMNA (0.53) LMNAKDM4ERAB9ASMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL17895944 0.74 SRD5A2 (0.38) SRD5A2RAB9AKMT2AMEN1NPC1
SCHEMBL1128867 0.74 LMNA (0.52) LMNAKDM4ERAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 SRD5A2 671/4885LMNA 3418/4885KDM4E 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.